Finance

Lists
EMCURE:NSE
Emcure Pharmaceuticals Ltd
₹ २,२३५.००
+०.८५%
(+१८.८०) 1D
नोभेम्बर ११, १५:३०:०० GMT+५:३०  ·   INR
All symbols
SymbolPriceChange% Change
Generating top insights for EMCURE...
Open
₹ २,२१६.२०
High
₹ २,२६०.००
Low
₹ २,२०३.००
Mkt. cap
४.२५ खरब
Avg. vol.
१.९२ लाख
Volume
२.१२ लाख
Dividend
०.१६%
Quarterly dividend
₹ ०.९०
Ex-dividend date
२०२६ सेप्टेम्बर ४
P/E ratio
४६.९१
52-wk high
₹ २,४२९.९०
52-wk low
₹ १,३१२.३०
EPS
₹ ४७.६४
No. of employees
७ हजार
Open
₹ २,२१६.२०
High
₹ २,२६०.००
Low
₹ २,२०३.००
Mkt. cap
४.२५ खरब
Avg. vol.
१.९२ लाख
Volume
२.१२ लाख
Dividend
०.१६%
Quarterly dividend
₹ ०.९०
Ex-dividend date
२०२६ सेप्टेम्बर ४
P/E ratio
४६.९१
52-wk high
₹ २,४२९.९०
52-wk low
₹ १,३१२.३०
EPS
₹ ४७.६४
No. of employees
७ हजार
News stories
From web sources and news partners
TV News Check
TV News Check
·
५४ मिनेट पहिले
Dow Gains 255, Nasdaq Rallies 400, S&P 500 Adds 98
Investing.com
Investing.com
·
५० मिनेट पहिले
U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.48%
Profile
Emcure Pharmaceuticals Limited is an Indian multinational pharmaceutical company, headquartered in Pune. Emcure's product portfolio includes tablets, capsules and injectables. The company produces gynaecology, cardiovascular, oncology and blood therapeutic drugs, HIV antivirals and other anti-infectives, and vitamins and minerals. Wikipedia
About Emcure Pharmaceuticals Ltd
CEOSatish Ramanlal Mehta
Employees६.९१ हजार
Founded१९८१ अप्रिल १६
Headquarters-
SectorHealth Care
Industry-
Websiteemcure.com
Last report
२०२६ नोभेम्बर ३
Fiscal period
Q2 2027
₹ १७.१४ / ₹ १४.९०
+१५.०३%beat
Revenue / Est. (INR)
२८.२० अरब / २६.५२ अरब
+६.३५%beat
Fiscal Q2 2027 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in INR
Loading Previous Earnings...
Revenue
Net income
All values in INR
२०२५ डिसेम्बर
२०२६ मार्च
२०२६ जुन
२०२६ सेप्टेम्बर
Revenue
२३.६३ अरब
२४.७० अरब
२५.८० अरब
२८.२० अरब
Cost of goods sold
९.६२ अरब
१०.९३ अरब
१०.७३ अरब
११.४२ अरब
Cost of revenue
९.६२ अरब
१०.९३ अरब
१०.७३ अरब
११.४२ अरब
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
३.८७ अरब
७.२१ अरब
४.०९ अरब
४.३५ अरब
Operating expense
१०.४६ अरब
९.९७ अरब
११.०९ अरब
१२.१३ अरब
Total operating expenses
२०.०८ अरब
२०.९० अरब
२१.८२ अरब
२३.५५ अरब
Operating income
३.५५ अरब
३.७९ अरब
३.९८ अरब
४.६५ अरब
Other non operating income
१.८५ करोड
-३६.३७ करोड
२.०७ करोड
३.२५ करोड
EBT including unusual items
३.१४ अरब
३.४१ अरब
३.९४ अरब
४.४६ अरब
EBT excluding unusual items
३.५२ अरब
३.७२ अरब
३.९२ अरब
४.४६ अरब
Income tax expense
८२.४२ करोड
९७.४४ करोड
१.०१ अरब
१.२१ अरब
Effective tax rate
२६.२७%
२८.५६%
२५.६७%
२७.०९%
Other operating expenses
५.५४ अरब
१.७० अरब
५.९० अरब
६.६९ अरब
Net income
२.३१ अरब
२.४३ अरब
२.९४ अरब
३.२६ अरब
Net profit margin
९.७५%
९.८६%
११.३९%
११.५४%
Earnings per share
१३.६७
१४.७०
१५.३४
१७.१४
Interest and investment income
-
१.६८ करोड
-
-
Interest expense
-३७.९८ करोड
-९.२५ करोड
-३१.५४ करोड
-३५.५८ करोड
Net interest expenses
-३७.९८ करोड
-७.५७ करोड
-३१.५४ करोड
-३५.५८ करोड
Depreciation and amortization charges
१.०५ अरब
१.०६ अरब
१.१० अरब
१.१० अरब
EBITDA
४.३७ अरब
४.६७ अरब
५.०२ अरब
५.७५ अरब
Gain or loss from assets sale
-
-
-
-
Upcoming events
AI content may include mistakes. Learn more
Google एपहरू